You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

374 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab,
trastuzumab,
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PACLitaxel,
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    leuprolide - long-acting formulation
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
leuprolide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tamoxifen
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab,
trastuzumab,
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
PACLitaxel,
gemcitabine,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2019
Regimen
Cancer Type:
Skin, 
Merkel Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CARBOplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2019

Pages